Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Jul 10, 2018 First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative breast cancer (TNBC)  IMpassion130 is the third positive Phase III study to demonstrate a clinical benefit with the investigational combination

Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions

May 16, 2018 Presentations highlight the value of innovative research in key disease areas including multiple myeloma, lymphoma, acute myeloid leukemia and squamous non-small cell lung cancer, as well as novel CAR T technology SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today

Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs

SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jennifer Dudinak, Pharm.D., as Senior Vice President, Global Regulatory Affairs, reporting to Jay Backstrom, M.D., Chief Medical Officer, effective April 30, 2018. Jennifer will be responsible for regulatory strategy and execution across Celgene’s portfolio

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability, gadolinium-enhanced lesion status and prior exposure to disease-modifying therapies versus interferon beta-1a (Avonex®) Ozanimod showed effects on cortical grey matter volume and

Celgene Corporation Announces Changes to Its Board of Directors

Gilla Kaplan, Ph.D., retiring from Board of Directors after 20 years of service US health insurance expert Patricia Hemingway Hall elected to Board of Directors Juno Therapeutics co-founder and former CEO Hans Bishop elected to Board of Directors SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) today announced changes

Celgene Corporation to Webcast at Upcoming Investor Conferences

SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences where Celgenemanagement will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s website